ORIC Pharmaceuticals Announces Participation in Investor Events
ORIC Pharmaceuticals to Attend Investor Conferences
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company, is focused on developing innovative treatments that combat mechanisms of therapeutic resistance. The management team has officially announced its participation in several prominent investor conferences scheduled for September.
Details of the Upcoming Conferences
Among the key events that ORIC Pharmaceuticals will participate in is the2024 Wells Fargo Healthcare Conference, where management will engage in a fireside chat on Thursday, September 5. This interactive discussion is set to begin at 8:00 a.m. ET, providing insights into the company’s strategic goals and innovations.
Following this, ORIC participants will also take part in theBaird 2024 Global Healthcare Conference on Tuesday, September 10, where a similar fireside chat will take place at 10:50 a.m. ET. Access to this session is exclusively available to conference attendees.
Lastly, ORIC will be featured at the2024 Cantor Global Healthcare Conference, with a fireside chat scheduled for Thursday, September 19 at 8:35 a.m. ET. These platforms serve as vital opportunities for ORIC to reach potential investors and share updates on advancements in their clinical programs.
Webcasts and Replays
Following the events, live webcasts of the discussions from both the Wells Fargo and Cantor conferences will be available. Interested parties can find these webcasts in the investor section of ORIC's official website. Additionally, replays of the webcasts will be accessible for a period of 90 days after the events.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is dedicated to enhancing patients’ lives by Overcoming Resistance In Cancer. Their pipeline features several promising clinical stage product candidates designed to address critical aspects of cancer treatment resistance.
Current Pipeline Overview
One of the leading candidates in their roster is ORIC-114, a potent brain-penetrant inhibitor that selectively targets EGFR and HER2, particularly focusing on exon 20 insertion mutations across various genetically defined cancers. This innovative therapy is gaining recognition in the oncology landscape.
Another significant product candidate is ORIC-944, an allosteric inhibitor directed at the polycomb repressive complex 2 (PRC2) via the EED subunit, which is designed for the treatment of prostate cancer. ORIC-533 also holds promise as an orally bioavailable small molecule inhibitor of CD73, playing a vital role in the adenosine pathway associated with resistance to chemotherapy and immunotherapy, particularly in multiple myeloma.
In addition to these, ORIC® is actively advancing multiple precision medicines that target various hallmark mechanisms of resistance in cancer therapies.
Company Presence
ORIC Pharmaceuticals operates offices located in South San Francisco and San Diego, California, positioning the company strategically within key biopharmaceutical hubs.
Contact Information
For more information regarding ORIC Pharmaceuticals, interested parties can visit their website, or contact:
Dominic Piscitelli, Chief Financial Officer
Email: dominic.piscitelli@oricpharma.com
Email: info@oricpharma.com
Frequently Asked Questions
What is ORIC Pharmaceuticals known for?
ORIC Pharmaceuticals specializes in the development of innovative therapies targeting mechanisms of resistance in cancer treatment.
When is ORIC participating in the upcoming investor conferences?
ORIC will participate in investor conferences throughout September, including events on the 5th, 10th, and 19th.
How can I access the webcasts of ORIC's investor conferences?
The webcasts will be accessible through the investor section of ORIC's official website, and replays will be available for 90 days after the events.
What are the key product candidates in ORIC's pipeline?
ORIC's key product candidates include ORIC-114, ORIC-944, and ORIC-533, each targeting specific cancer-related mechanisms of resistance.
Where is ORIC Pharmaceuticals headquartered?
ORIC Pharmaceuticals has offices in South San Francisco and San Diego, California, enhancing their presence in influential biopharmaceutical markets.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Snap-on Incorporated Plans to Broadcast Third Quarter Results
- Gold Reserve's Update Signals Progress in Sale Proceedings
- Orbis Medicines Unveils R&D Expansion at Copenhagen Hub
- Exciting Gold Intersections Reported by Kobo Resources' Drilling
- Exciting New Store Launch of Red White & Blue Thrift Store
- Exploring Defensive Stocks with Exceptional Dividend Yields
- Libro Achieves Remarkable 536% Growth, Ranking 75th in Canada
- Unlocking New Exploration Potential: Nevada King Gold Corp.
- RIV Capital and Cansortium Debut MOODS Cannabis Line in NY
- Constellation Brands Shows Strong Growth in Fiscal Q2 Results
Recent Articles
- Aura Biosciences Presents Phase 2 Data on Bel-sar Treatment
- Avista Announces Leadership Transition as CEO Dennis Vermillion Retires
- Structure Therapeutics Engages with Investors at Key Conferences
- Calavo Growers Inc. to Announce Q3 Financial Results
- DSS, Inc. Appoints Jason Grady as Interim CEO
- Shuttle Pharmaceuticals Faces Nasdaq Listing Non-Compliance
- Pineapple Energy Reports on Recent Financial Performance Insights
- DeNube Launches Revolutionary Decentralized GPU Cloud Network
- Massey Ferguson 9S Series Tractor: A Game Changer for Farmers
- Nvidia Earnings: An Underpriced Risk for Investors
- Oroco Resource Corp. PEA Update Webinar and Report Filing
- McEwen Mining Partners for 100% Renewable Energy in Copper Project
- Tech Stocks Struggle as Nvidia Earnings Approach
- Harvard Apparatus Secures $5 Million for Clinical Advancements
- Understanding Medical Properties Trust's Dividend Cut
- Understanding Roth IRAs and the Social Security Tax
- Understanding the Recent Decline of Icahn Enterprises
- Industrial Food Blanchers Market to Reach USD 574 Billion
- Brady Corporation to Host Earnings Conference Call
- Union Claims Against Chipotle Highlight Labor Rights Issues
- Nvidia Prepares for Second Quarter Earnings Report
- Ergodyne's Advanced Tool Tethering Solutions Announced
- Associa Canada Achieves Great Place To Work Certification
- Kingswood Capital Partners Closes $8 Million IPO for WORK MedTech
- Pixalate's Q2 2024 Fraudulent CTV Bundle IDs Report
- Aesthetic Medicine Market Growth to USD 205.32 Billion
- MasHash Unveils Revolutionary Cloud Mining Platform
- Mowi ASA (OSE: MOWI) Announces Senior Executive Share Options
- PDD Holdings Faces Challenges Amidst Growth Fluctuations
- V3V Ventures Bolsters Blockchain Innovation with U2U and CrossCurve
- WORK Medical Technology Group LTD Completes IPO Successfully
- Jack Dorsey's Vision for Block as a Crypto Leader
- Key Insights on Upcoming Stock Splits This Week
- Shell plc Announces Share Buy-Back Transactions
- Dermal Fillers Market Growth and Trends
- Growth Prospects of the Wire Cutting Machine Market
- BioNexus Gene Lab Invests RM 1 Million in AI Healthcare Tech
- Genmab to Share Insights at Global Healthcare Conference
- Mixed Market Performance as Investors Eye Nvidia Earnings
- Associa Achieves Prestigious Great Place to Work Standard
- Automotive Auxiliary Lamps Market Growth Forecasts
- Intragastric Balloons Market Growth Insights and Trends
- Immunoassay Market Set to Thrive with 5.8% CAGR Growth
- NBME Launches Fee Assistance Program for Medical Students
- Blank Rome Expands Boston Office with Fraser Collin
- Endeavors Unlimited and Morgan’s MAC Partner for Disability Support
- Wreaths Across America Encourages Nationwide Flag Waving
- GDMining's Innovative Cloud Mining Service Redefines Accessibility
- Rexel's Share Buyback Activity Report
- Solvay Expands Share Buyback Program with Recent Acquisitions